Cellular and antibody response in GMZ2-vaccinated Gabonese volunteers in a controlled human malaria infection trial.
Odilon NouatinJavier IbáñezRolf FendelUlysse A NgoaFreia-Raphaella LorenzJean-Claude Dejon-AgobéJean Ronald EdoaJudith FlüggeSina BrücknerMeral EsenMichael TheisenStephen L HoffmanKabirou MoutairouAdrian J F LutyBertrand LellPeter G KremsnerAyola A AdegnikaBenjamin MordmüllerPublished in: Malaria journal (2022)
In lifelong malaria exposed adults, the main marker of protection against CHMI is a broad antibody pattern recognizing multiple stages of the plasmodial life cycle. Despite vaccination with GMZ2 using a novel formulation, expansion of the GMZ2-stimulated T cells or the GMZ2-specific B cell response was limited, and the vaccine response could not be identified as a marker of protection against malaria. Trial registration PACTR; PACTR201503001038304; Registered 17 February 2015; https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=1038.